mFOLFORINOX

DRUG3 trials

Sponsors

Yuhong Li, Centre Hospitalier Universitaire Dijon, Akeso

Conditions

Ampullary AdenocarcinomaPancreas CancerPancreas Cancer, Duct Cell AdenocarcinomaPancreatic Cancer Resectable

Phase 1

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Not yet recruitingNCT06913218

AkesoPancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma

Start: 2025-07-22End: 2028-11-06Target: 60Updated: 2025-04-06

Phase 2

Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

CompletedNCT04224402

Yuhong LiPancreatic Cancer Resectable

Start: 2020-01-31End: 2022-12-31Updated: 2023-02-15

Phase 3

PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma

RecruitingNCT06813976

Centre Hospitalier Universitaire DijonAmpullary Adenocarcinoma

Start: 2025-07-02End: 2033-07-31Target: 294Updated: 2025-07-11